Product NewsMalignant melanoma identified as disease target for YP004, York Pharma’s skin cancer programme
Product NewsBiométhodes annonce un nouveau succès de Massive Mutagenesis® pour l’optimisation d’anticorps
Product NewsBiométhodes reports a new success in antibody optimisation using Massive Mutagenesis®
Product NewsMorphoSys and Chemicon International Enter into Worldwide Licensing Agreement for Research Antibodies
Product NewsSYMPHOGEN’S SUCCESS IN MANUFACTURING CONSISTENT BATCHES OF POLYCLONAL ANTIBODIES FOR CLINICAL TRIALS ATTRACTS NEW USD 25 MILLION INVESTMENT
